Resistance to BRAF Inhibitors: EZH2 and Its Downstream Targets as Potential Therapeutic Options in Melanoma
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24031963 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Anne Uebel und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venereology, University Hospital Halle (Saale), Martin-Luther-University Halle-Wittenberg, 06120 Halle (Saale), Germany. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Faculty of the Martin-Luther-University Halle-Wittenberg Wilhelm Roux Funding Program, Hiege Stiftung - Die Deutsche Hautkrebsstiftung, Wilhelm Roux Funding Program.
Abstract (Originalsprache)
Activating BRAF mutations occurs in 50–60% of malignant melanomas. Although initially treatable, the development of resistance to BRAF-targeted therapies (BRAFi) is a major challenge and limits their efficacy. We have previously shown that the BRAFV600E signaling pathway mediates the expression of EZH2, an epigenetic regulator related to melanoma progression and worse overall survival. Therefore, we wondered whether inhibition of EZH2 would be a way to overcome resistance to vemurafenib. We found that the addition of an EZH2 inhibitor to vemurafenib improved the response of melanoma cells resistant to BRAFi with regard to decreased viability, cell-cycle arrest and increased apoptosis. By next-generation sequencing, we revealed that the combined inhibition of BRAF and EZH2 dramatically suppresses pathways of mitosis and cell cycle. This effect was linked to the downregulation of Polo-kinase 1 (PLK1), a key regulator of cell cycle and proliferation. Subsequently, when we inhibited PLK1, we found decreased cell viability of melanoma cells resistant to BRAFi. When we inhibited both BRAF and PLK1, we achieved an improved response of BRAFi-resistant melanoma cells, which was comparable to the combined inhibition of BRAF and EZH2. These results thus reveal that targeting EZH2 or its downstream targets, such as PLK1, in combination with BRAF inhibitors are potential novel therapeutic options in melanomas with BRAF mutations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Venereology, University Hospital Halle (Saale), Martin-Luther-University Halle-Wittenberg, 06120 Halle (Saale), Germany.
- Department of Internal Medicine IV, Oncology/Hematology, Martin-Luther-University Halle-Wittenberg, 06120 Halle (Saale), Germany.
Förderung
- Medical Faculty of the Martin-Luther-University Halle-Wittenberg Wilhelm Roux Funding Program
- Hiege Stiftung - Die Deutsche Hautkrebsstiftung
- Wilhelm Roux Funding Program
- German Research Foundation (DFG)
- Hiege Stiftung—Die Deutsche Hautkrebsstiftung
Zitieren
APA
Uebel, A., Kewitz-Hempel, S., Willscher, E., Gebhardt, K., Sunderkötter, C., & Gerloff, D. (2023). Resistance to BRAF Inhibitors: EZH2 and Its Downstream Targets as Potential Therapeutic Options in Melanoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24031963
Vancouver
Uebel A, Kewitz-Hempel S, Willscher E, Gebhardt K, Sunderkötter C, Gerloff D. Resistance to BRAF Inhibitors: EZH2 and Its Downstream Targets as Potential Therapeutic Options in Melanoma. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24031963
BibTeX
@article{Uebel2023,
author = {Uebel, Anne and Kewitz-Hempel, Stefanie and Willscher, Edith and Gebhardt, Kathleen and Sunderkötter, Cord and Gerloff, Dennis},
title = {Resistance to BRAF Inhibitors: EZH2 and Its Downstream Targets as Potential Therapeutic Options in Melanoma},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24031963}
}
EUVIMED